Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Christian Petersen

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Thrombosis Research|August 12, 2008
Microarray studies of factor VIIa-activated cancer cellsLars Christian Petersen
Frontiers in Bioscience (Landmark Edition)|May 31, 2011
Tissue factor and factor VIIa cross-species compatibilityTom Knudsen, Ole Hvilsted Olsen, Lars Christian Petersen
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 9, 2011
Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogsHenrik Agersø, Niels Rode Kristensen, Henrik Østergaard, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 27, 2014
Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administrationHenrik Agersø, Rune Viig Overgaard, Mads Bjelke Petersen, et al.
Thrombosis Research|January 8, 2014
Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway InhibitorLene Hansen, Lars Christian Petersen, Brian Lauritzen, et al.
Blood|May 8, 2012
Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia modelIda Hilden, Brian Lauritzen, Brit Binow Sørensen, et al.
Blood|June 25, 2011
Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptideHenrik Østergaard, Jais R Bjelke, Lene Hansen, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Thrombosis Research|August 12, 2008
Microarray studies of factor VIIa-activated cancer cellsLars Christian Petersen
Frontiers in Bioscience (Landmark Edition)|May 31, 2011
Tissue factor and factor VIIa cross-species compatibilityTom Knudsen, Ole Hvilsted Olsen, Lars Christian Petersen
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 9, 2011
Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogsHenrik Agersø, Niels Rode Kristensen, Henrik Østergaard, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 27, 2014
Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administrationHenrik Agersø, Rune Viig Overgaard, Mads Bjelke Petersen, et al.
Thrombosis Research|January 8, 2014
Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway InhibitorLene Hansen, Lars Christian Petersen, Brian Lauritzen, et al.
Blood|May 8, 2012
Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia modelIda Hilden, Brian Lauritzen, Brit Binow Sørensen, et al.
Blood|June 25, 2011
Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptideHenrik Østergaard, Jais R Bjelke, Lene Hansen, et al.
Pageof 1